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OBJECTIVES This study was designed to establish the clinical significance of antibodies against oxidized
low density lipoprotein (anti-Ox-LDL) titer in atherosclerotic coronary artery disease
(CAD).
BACKGROUND Oxidative modification of LDL, which plays a key role in the development of atherosclerosis,
induces immunogenic epitopes in the LDL molecule, and the presence of anti-Ox-LDL has
been demonstrated in human sera.
METHODS Anti-Ox-LDL titer was measured by enzyme-linked immunosorbent assay in 108 patients
who had angiographically verified CAD, and 31 patients who had chest pain but no
significant CAD, as controls.
RESULTS The anti-Ox-LDL titer was higher (p , 0.01) in patients with multivessel CAD (19.4 6
10.1 AcU/ml, n 5 68) than in the controls (9.8 6 4.1). However, no significant difference was
shown between the single-vessel CAD group (15.1 6 6.4, n 5 40) and the controls, or
between the multivessel CAD group and the single-vessel CAD group. The titer was higher
in patients with unstable angina (21.5 6 11.8 AcU/ml, n 5 20, p , 0.01), or in patients with
acute myocardial infarction (23.1 6 12.0, n 5 20, p , 0.01) than in patients with stable-effort
angina or old myocardial infarction (12.2 6 8.6, n 5 68). Multiple logistic regression analysis
indicated that the anti-Ox-LDL titer most powerfully discriminated CAD patients from
controls (odds ratio [OR]: 1.20, 95% confidence interval [CI]: 1.07–1.33, p 5 0.0006) and
acute coronary syndrome from chronic CAD (OR: 1.09, 95% CI: 1.04–1.14, p 5 0.0008).
CONCLUSIONS Serum anti-Ox-LDL titer not only can predict a presence of atherosclerotic CAD but also
may be a marker of plaque instability. Low density lipoprotein oxidation may play an
important role in the development of plaque instability. (J Am Coll Cardiol 2001;37:775–9)
© 2001 by the American College of Cardiology
Oxidized low density lipoprotein (LDL) is believed to play
a key role in the development of atherosclerosis (1). It has
been proposed that oxidative modification of LDL is a
prerequisite for rapid accumulation of LDL in macrophages
and for foamy cell formation. The LDL extracted from
atherosclerotic lesions certainly shows biochemical and im-
munoreactive properties similar to those of in vitro oxidized
LDL (2). Oxidative modification of LDL induces immu-
nogenic epitopes in the LDL molecule (3), and the presence
of antibodies against oxidized LDL (anti-Ox-LDL) has
been demonstrated in human sera (4,5). Results of several
studies demonstrated the increased titer of anti-Ox-LDL in
patients with atherosclerotic coronary artery disease (CAD)
(6–8) as well as cerebral (9) or peripheral (10) artery disease.
Conversely, other studies reported that no positive relation-
ship was observed between anti-Ox-LDL titers and the
extent of atherosclerosis (11–13). The purpose of this study
was to establish the clinical significance of measuring
anti-Ox-LDL titer in atherosclerotic CAD.
METHODS
Patient Selection and Angiographic Assessment
In this study we enrolled 108 patients who underwent initial
diagnostic coronary angiography and had significant athero-
sclerotic CAD. Diagnostic criteria of angiographically sig-
nificant CAD included organic-discrete stenotic lesions as
indicating more than 75% diameter stenosis. The criterion
for single-vessel CAD or multivessel CAD was based upon
the number of arteries with a more than 75% diameter
stenosis. Eighty-eight patients underwent scheduled coro-
nary angiography. These included 68 patients with stable-
effort angina or old myocardial infarction (OMI) and 20
patients with unstable angina, which was defined as an
increase in the frequency and/or severity of chest pain or
new onset of symptoms suggesting myocardial ischemia. In
patients with unstable angina, only those who were sched-
uled for coronary angiography within seven days from the
last ischemic evidence were enrolled. The remaining 20
patients included those with acute myocardial infarction
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(AMI) who underwent coronary angiography in the emer-
gent situation. Excluded were patients who underwent prior
coronary angioplasty or coronary bypass surgery and those
with other cardiac or vascular diseases including cardiomy-
opathy, congenital or valvular heart disease, atherosclerotic
peripheral artery diseases, or cerebrovascular diseases.
Thirty-one patients who complained of chest pain but had
no angiographically detectable CAD (defined as having
neither discrete stenosis nor vessel wall irregularity) and who
showed negative acetylcholine provocation test and whose
age and gender were matched with the CAD patients were
selected as controls. The study protocol was approved by the
Dokkyo University Institutional Review Board, and written
informed consent was obtained from each patient.
Lipid Profile
Venous blood samples were taken in the fasting state in 88
patients with CAD and 31 control subjects early in the
morning on the day of coronary angiography. In 20 patients
with AMI, blood samples were taken on admission before
the start of emergent coronary angiography. Routine lipid
profile and glucose metabolism were examined. The residual
serum was frozen at 280°C until the analysis of anti-Ox-
LDL. Serum total cholesterol and triglyceride levels were
determined by automated enzymatic assays (14,15). Low
density lipoprotein cholesterol was assayed by enzymatic
measurement, and high density lipoprotein (HDL) choles-
terol was determined by a precipitation method. Apoli-
poprotein (apo) A-I, apo B and apo E were quantified with
a turbidimetric immunoassay. The assay of lipoprotein (a)
[Lp(a)] was conducted by a latex agglutination immunoas-
say.
Assay of anti-Ox-LDL
The quantification of anti-Ox-LDL was performed using
an enzyme-linked immunosorbent assay (ELISA) kit (Ox-
LDL IgG ELISA Test; Biodesign International, Saco,
Maine), as reported elsewhere (6–9). Briefly, serum was
diluted with sample diluent at 1:21. Microtiter ELISA
plates were precoated with malonic dialdehyde (MDA)-
induced Ox-LDL. Next, 100 ml of diluted specimen was
added to each well and incubated at 37°C for 30 min. After
the wells were washed five times, enzyme-labeled anti-
human IgG was added and incubated at 37°C for 30 min.
The wells were again washed five times. The substrate
containing p-nitrophenyl phosphate (p-NPP) was added
and incubated at 37°C for 30 min. The reaction was stopped
by 1.5 mol/liter sodium hydroxide. The absorbance was read
at the wavelength of 405 nm.
Statistical Analysis
The data are expressed as mean 6 SD. Comparisons
between the two groups were performed with unpaired t
tests for continuous variables and chi-square tests for cate-
gorical variables. Comparisons among the three groups were
performed with one-way analysis of variance (ANOVA)
followed by the Student-Newman-Keuls test for multiple
comparisons for continuous variables, or Kruskal-Wallis
ANOVA on ranks followed by the Dann test for categorical
variables. A multiple logistic regression model was used for
discriminating CAD patients from control subjects or dis-
criminating patients with acute coronary syndrome from
patients with chronic CAD. Of the independent variables,
presence of hypertension or diabetes mellitus and smoking
habits were treated as categorical variables. The levels of
total cholesterol, triglyceride, HDL cholesterol, LDL cho-
lesterol and the anti-Ox-LDL titer were treated as contin-
uous variables. A p value , 0.05 was considered to be
significant.
RESULTS
Of 108 patients, 40 had single-vessel CAD, and 68 had
multivessel (double- or triple-vessel) CAD. Comparisons of
conventional coronary risk factors (hypertension, diabetes
mellitus, smoking habits and the lipid profile) among the
patient groups of control, single-vessel CAD and multives-
sel CAD are shown in Table 1. The HDL-cholesterol level
was lower in the multivessel CAD group than in the
controls. The remaining risk factors were identical among
the three patient groups. The anti-Ox-LDL titer was
19.4 6 10.1 AcU/ml in the multivessel CAD group, which
was higher than the value of 9.8 6 4.1 AcU/ml in the
controls (p , 0.01). No significant difference in the values
of anti-Ox-LDL titer was seen between the single-vessel
CAD group (15.1 6 6.4) and the controls, and between the
multivessel CAD group and the single-vessel CAD group
(Fig. 1). Multiple logistic regression analysis indicated
that the anti-Ox-LDL titer as well as the HDL choles-
terol level but not other conventional coronary risk
factors could discriminate CAD patients from control
subjects. The anti-Ox-LDL (odds ratio [OR]: 1.20, 95%
confidence interval [CI]: 1.07–1.33, p 5 0.0006) was a
more powerful discriminating factor than the HDL choles-
terol level (OR: 0.89, 95% CI: 0.81–0.97, p 5 0.003)
(Table 2).
Abbreviations and Acronyms
AMI 5 acute myocardial infarction
ANOVA 5 one-way analysis of variance
anti-Ox-LDL 5 antibodies against oxidized low density
lipoprotein
apo 5 apolipoprotein
CAD 5 coronary artery disease
CI 5 confidence interval
ELISA 5 enzyme-linked immunosorbent assay
HDL 5 high density lipoprotein
LDL 5 low density lipoprotein
Lp(a) 5 lipoprotein (a)
MDA 5 malonic dialdehyde
OMI 5 old myocardial infarction
OR 5 odds ratio
p-NPP 5 p-nitrophenyl phosphate
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Within the 108 CAD patients, the anti-Ox-LDL titer
was higher in patients with unstable angina (21.5 6 11.8
AcU/ml, p , 0.01) or AMI (23.1 6 12.0 AcU/ml, p ,
0.01) than in patients with stable-effort angina or OMI
(12.2 6 8.6) (Fig. 2). In the multiple logistic regression
model, the anti-Ox-LDL titer as well as smoking habits but
not other conventional coronary risk factors could discrim-
inate 40 patients with acute coronary syndrome (i.e., unsta-
ble angina or AMI) from 68 patients with chronic CAD
(i.e., stable-effort angina or OMI). The anti-Ox-LDL (OR:
1.09, 95% CI: 1.04–1.14, p 5 0.0008) was a more powerful
discriminating factor than smoking habits (OR: 3.74, 95%
CI: 1.22–11.44, p 5 0.02) (Table 3).
DISCUSSION
Immunological Response to Oxidized LDL
There has been considerable interest recently in the contri-
bution of oxidative process of LDL (Ox-LDL) to the
development of atherosclerosis (1). Whereas native LDL
does not cause cholesterol ester accumulation in macro-
phages, modified LDL by oxidation does (16). Ox-LDL
has also been implicated in other mechanisms potentially
involved in the development of atherosclerosis—that is,
cytotoxic (17) or chemotactic action for monocytes (18) and
inhibition of macrophage motility (19). Furthermore, the
involvement of oxidation in atherosclerosis is supported by
the results of clinical studies. Both elevated lipid peroxide
levels (20) and increased susceptibility of LDL to in vitro
oxidation (21) are associated with atherosclerosis, and in-
creased dietary consumption of antioxidants appears to be
associated with a decreased risk for CAD (22,23).
To evaluate this phenomenon further, reliable assays for
LDL oxidation state are necessary. However, the direct
measurement of Ox-LDL in serum or plasma is compli-
cated by the potential for in vivo modification of the sample
and also by the possibility that the primary location of the
analyses of the interest may not be the circulation. In
addition, oxidation leads to an array of potential forms,
which appear at different stages of the oxidation process and
may have varied significance (24). In contrast, the measure-
ment of anti-Ox-LDL titer can provide us stable data.
Specific immunological epitopes expressed on Ox-LDL
were found in atherosclerotic lesions both in animals with
experimental atherosclerosis and in humans (2,3). Expres-
sion of such epitopes in vitro can be generated by various
procedures, including incubation with endothelial cells and
macrophages, oxidation in the presence of copper ions and
the treatment with MDA (3). Ox-LDL can interact with
scavenger receptors of monocyte-derived macrophages. It is
suggested that these interactions can induce the formation
of anti-Ox-LDL (25). Therefore, anti-Ox-LDL can be
considered a marker of LDL oxidation in the level of tissues
or cells.
Antibody Against Oxidized LDL as a Predictor of CAD
We demonstrated in this study that anti-Ox-LDL titer was
higher in patients with multivessel CAD than in patients
with single-vessel CAD or in control patients, although it
showed no significant difference in single-vessel CAD
patients and controls. This result indicated that the anti-
Ox-LDL titer level was elevated in patients with severe
CAD but not in patients with mild CAD. The multiple
logistic regression analysis showed that the anti-Ox-LDL
titer and HDL cholesterol level but not any other conven-
tional coronary risk factors could discriminate CAD pa-
tients from control subjects. In addition, the anti-Ox-LDL
Table 1. Comparison of Coronary Risk Factors in Three Patient
Groups of Single-Vessel CAD, Multivessel CAD and Controls
Controls
(n 5 31)
Single-Vessel
CAD
(n 5 40)
Multivessel
CAD
(n 5 68)
Age (yrs) 61 6 10 62 6 11 61 6 10
Male gender 18 (58%) 31 (78%) 53 (78%)
Diabetes 4 (13%) 7 (18%) 13 (19%)
Hypertension 12 (39%) 12 (30%) 26 (38%)
Smoking 18 (58%) 28 (70%) 44 (65%)
Total cholesterol (mg/dl) 194 6 18 202 6 19 203 6 24
Triglyceride (mg/dl) 104 6 43 102 6 42 101 6 46
HDL cholesterol (mg/dl) 45 6 12 43 6 10 38 6 8*
LDL cholesterol (mg/dl) 116 6 29 123 6 32 129 6 28
Apo A-I (mg/dl) 113 6 20 113 6 19 106 6 18
Apo B (mg/dl) 92 6 21 92 6 21 98 6 15
Apo E (mg/dl) 3.3 6 0.8 3.3 6 0.8 3.2 6 0.8
Lp(a) 21 6 26 23 6 31 23 6 25
*p , 0.01.
CAD 5 coronary artery disease; HDL 5 high density lipoprotein; LDL 5 low
density lipoprotein; apo 5 apolipoprotein; Lp(a) 5 lipoprotein (a).
Figure 1. Comparison of anti-Ox-LDL titer among the patient groups of
control, single-vessel CAD and multivessel CAD. The titer was higher in
the multivessel CAD group than in controls. No significant difference was
seen between the single-vessel CAD group and the controls, or between
the multivessel CAD group and the single-vessel CAD group. Anti-Ox-
LDL 5 antibodies against oxidized low density lipoprotein; CAD 5
coronary artery disease; NS 5 not significant.
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titer was a more powerful predicting factor than HDL
cholesterol. These results suggest that the anti-Ox-LDL
may be a potent predictor of CAD. Elevated levels of
anti-Ox-LDL titer in patients with CAD have also been
reported elsewhere. Maggi et al. (7) demonstrated that high
titer of anti-Ox-LDL was observed not only in patients
with CAD but also in patients without clinically relevant
signs of CAD but considered at risk. Their results indicate
that the anti-Ox-LDL titer may be useful in predicting
early-stage CAD, whereas our results suggest that the
anti-Ox-LDL titer may be a marker of advanced CAD.
Antibodies against oxidized LDL titer also increased in
other atherosclerotic disease besides CAD. Bergmark et al.
(10) demonstrated by a case-controlled study that anti-Ox-
LDL titer discriminated patients with atherosclerotic pe-
ripheral vascular disease. A prospective ultrasound observa-
tion of carotid atherosclerosis by Salonen et al. (9) indicated
that anti-Ox-LDL titer was correlated with the rate of
lesion progression but not with the baseline intima-media
thickness.
Antibody against oxidized LDL as a marker of plaque
instability. In our study, patients with unstable angina or
patients with AMI showed higher titer of anti-Ox-LDL
than patients with stable-effort angina or OMI. Further-
more, our multiple regression analysis results showed the
anti-Ox-LDL titer could most strongly discriminate acute
coronary syndrome (i.e., unstable angina or AMI) from
chronic CAD (i.e., stable-effort angina or OMI). These
results suggest that the anti-Ox-LDL may be a marker of
plaque instability. Several recent studies suggested that
Ox-LDL was related not only to onset or progression of
coronary atherosclerosis but also to plaque instability
(26,27). In the present study, we employed a commercial kit
for anti-Ox-LDL measurement. In this assay, we measured
an antibody against an epitope of MDA-induced-Ox-LDL.
Holvoet et al. (28) demonstrated that the plasma level of
MDA-modified LDL was threefold higher in patients with
acute coronary syndrome than in patients with stable angina
as well as normal volunteers. Ryan et al. (29) reported that
high levels of MDA-LDL antibodies were found in patients
with AMI and that the highest level was seen within 48 h
from its onset. In addition, Puurunen et al. (6) and Wu et
al. (30) presented data indicating that antibodies against
MDA-induced Ox-LDL could predict the occurrence of
AMI. These results suggest that the anti-Ox-LDL titer
may be a marker of unstable plaque presence and that
MDA-induced LDL oxidation may play an important role
in the development of plaque instability.
CONCLUSIONS
Finally, from this study we suggest that serum anti-Ox-
LDL titer not only can predict a presence of atheroscle-
rotic CAD but may also be a marker of plaque instability.
The LDL oxidation on local vascular wall seems to be
associated with plaque instability. Lipid anti-oxidation as
well as lipid lowering should be considered as a thera-
peutic strategy to inhibit plaque instability in atheroscle-
rotic CAD.
Figure 2. Comparison of anti-Ox-LDL titer among the patients with
stable-effort angina or OMI, unstable angina, and AMI. The titer was
higher in patients with unstable angina or AMI than in patients with
stable-effort angina or OMI. AMI 5 acute myocardial infarction; anti-
Ox-LDL 5 antibodies against oxidized low density lipoprotein; AP 5
angina pectoris; OMI 5 old myocardial infarction.
Table 2. Multiple Logistic Regression Analysis for Discriminating CAD Patients From
Control Subjects
Coefficient Wald x2 p Value
Odds Ratio
(95% CI)
Hypertension 20.235 0.221 0.638 0.79 (0.29–2.11)
Diabetes 0.875 1.593 0.207 2.39 (0.61–9.32)
Smoking 0.100 0.037 0.847 1.10 (0.40–3.06)
Total cholesterol (mg/dl) 0.028 1.632 0.201 1.02 (0.98–1.07)
Triglycerides (mg/dl) 20.013 3.642 0.056 1.03 (0.97–1.06)
HDL cholesterol (mg/dl) 20.112 9.046 0.003 0.89 (0.81–0.97)
LDL cholesterol (mg/dl) 0.011 0.003 0.621 1.00 (0.96–1.04)
Anti-Ox-LDL 0.169 11.888 0.0006 1.20 (1.07–1.33)
Anti-Ox-LDL 5 antibody against oxidized low density lipoprotein; CAD 5 coronary artery disease; CI 5 confidence interval;
HDL 5 high density lipoprotein; LDL 5 low density lipoprotein.
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